BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16267023)

  • 1. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
    Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA
    Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
    Lun XQ; Zhou H; Alain T; Sun B; Wang L; Barrett JW; Stanford MM; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2007 Sep; 67(18):8818-27. PubMed ID: 17875723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
    Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
    Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA
    Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reovirus as an oncolytic agent against experimental human malignant gliomas.
    Wilcox ME; Yang W; Senger D; Rewcastle NB; Morris DG; Brasher PM; Shi ZQ; Johnston RN; Nishikawa S; Lee PW; Forsyth PA
    J Natl Cancer Inst; 2001 Jun; 93(12):903-12. PubMed ID: 11416111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
    Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
    Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.
    Zemp FJ; McKenzie BA; Lun X; Maxwell L; Reilly KM; McFadden G; Yong VW; Forsyth PA
    PLoS One; 2013; 8(6):e65801. PubMed ID: 23762429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
    Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
    Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
    McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
    Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
    Stanford MM; Barrett JW; Nazarian SH; Werden S; McFadden G
    J Virol; 2007 Feb; 81(3):1251-60. PubMed ID: 17108021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
    Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
    PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
    Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
    Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
    Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.
    Barrett JW; Alston LR; Wang F; Stanford MM; Gilbert PA; Gao X; Jimenez J; Villeneuve D; Forsyth P; McFadden G
    J Neurovirol; 2007 Dec; 13(6):549-60. PubMed ID: 18097886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.